CLL-1 CAR-T for children with relapsed or refractory AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new cell therapy (CLL-1 CAR-T) for children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The therapy uses your child's own immune cells to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 3 and 18 years old and weighs at least 22 pounds (10 kg).
- They have been diagnosed with AML that has returned or not responded to treatment, and no other standard options are available.
- At least half of their leukemia cells must have a protein called CLL-1 (a specific marker on the cancer cells).
- Your child must be well enough to have a good ability to perform daily activities (a Karnofsky or Lansky score above a certain level).
- Their major organs (liver, kidneys, blood, lungs, and heart) must be working well enough.
- Any side effects from prior treatments must have mostly gone away.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-step treatment: first a targeted immune cell therapy (CLL1 CAR-T) to attack leukemia cells, followed by a stem cell transplant to rebuild healthy blood cells. It is for people with acute myeloid leukemia that has returned or not responded to previous chemotherapy.
This trial tests a new type of immune cell therapy (CAR-T) that targets three proteins (CLL1, CD33, NKG2D) on leukemia cells in patients with acute myeloid leukemia that has not responded to or come back after prior treatment.
This trial tests a combination of CAR-T cell therapies (targeting CD123, CLL-1, and CD7) followed by a stem cell transplant for people with acute myeloid leukemia that has returned or not improved. The goal is to see if this approach can help eliminate the leukemia and prepare for a transplant.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
This trial tests a new treatment called universal CLL1 CAR-T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to standard treatments. It aims to see if these specially designed immune cells can find and attack leukemia cells that carry a marker called CLL1.
Hear when a new CAR-T trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.